The Danish Medicines Agency has granted Perth-based medical cannabis company Little Green Pharma (ASX: LGP) registration for its 16% THC Billiniol LGP cannabis flower medicine.
Billinol LGP will be the first locally produced cannabis medicine to receive registration from the government, and it’s only the second supplier to have a cannabis flower product registered in Denmark. Danish medical cannabis users currently only have access to a handful of legal cannabis products, including Epidiolex and Sativex.
LGP is launching its products into Europe as part of an international expansion strategy that encompasses several key countries, including France and Poland. As Denmark has a mutual recognition scheme with Sweden, Finland and Norway, people in these countries will also be allowed to access Billiniol LGP through Danish distributors. As a result, LGP says launching Billinol LGP in Denmark will give the company access to the 27 million people in the Nordic region.
The registration aligns with LGP’s highly successful strategy of being first to market in key territories, enabling it to rapidly build a brand reputation for quality products and service with new market participants.
LGP expects to give the first batch of Billiniol LGP to Danish patients before the end of December. It has taken LGP two and a half years to two and a half years to get Billiniol LGP registered in Denmark, as, like Australia, the registration process is rigorous.
LGP will distribute Billiniol LGP in 5-gram alubag pouches that will retail for KK 140 – 160 ($AU29 – $32) a gram. That price is slightly higher than Australian prices, as Billiniol LGP retails for $13 – $22 a gram here.
